New biomarkers in the risk stratification of patients with suspected acute myocardial infarction
- 30 Downloads
The acute coronary syndromes (ACS) remain a diagnostic and prognostic challenge for today’s physician. Over the past decade, studies have identified several serologic biomarkers to aid the clinician in assessing risk and predicting outcomes in ACS. Still others are being identified that show promise for increasing the accuracy with which this risk is assessed. However, further research remains necessary to identify the perfect cardiac biomarker or combination of markers and to define their roles in clinical management of ACS patients.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.The Joint European Society of Cardiology/American College of Cardiology Committee: Myocardial infarction redefined—a consensus statement of the joint ECS/ACC committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000, 36:959–969. This reference provides the revised criteria for definition of MI reflecting broad international consensus. The redefinition emphasizes the diagnostic sensitivity and prognostic importance of troponin testing and also provides standards for defining the reference limit and assay precision at the reference limit.CrossRefGoogle Scholar
- 5.Ottani F, Galvani M, Nicolini FA, et al.: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000, 140:917–927. A thorough and well-done systematic overview and meta-analysis of the results of studies of troponin testing across the spectrum of ACS presentations. Clearly presents the prognostic importance of baseline troponin elevations in both ST-segment elevation and non-ST-segment elevation ACS.PubMedCrossRefGoogle Scholar
- 12.Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189–198. Meta-analysis of all trials of GP IIb/IIIa inhibitors in ACS clearly demonstrating the troponin status by treatment interaction in which patients who are troponin-positive at baseline derive enhanced benefit from treatment with GP IIb/IIIa inhibitors relative to patients who are troponin-negative at baseline.PubMedCrossRefGoogle Scholar
- 13.Morrow DA, Cannon CP, Rifai N, et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non- ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286:2405–2412.PubMedCrossRefGoogle Scholar
- 17.Newby LK, Storrow AB, Gibler WB, et al.: Bedside multimarker testing for risk stratification in chest pain units: the CHECKMATE study. Circulation. 2001, 103:1832–1837. This is the first prospective study to demonstrate the importance of a multimarker strategy of biomarker testing including myoglobin, and performed at the point of care to identify and risk stratify high-risk patients from among those with low-risk presentations with chest pain and nondiagnostic ECGs.PubMedGoogle Scholar
- 21.Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease. JAMA. 2001, 286:2107–2113. This study demonstrates that a marker of inflammation, interleukin- 6, may be useful in discriminating acute coronary syndrome patients who could benefit preferentially from an early invasive strategy of management.PubMedCrossRefGoogle Scholar
- 22.De Lemos JA, Marrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014–1021. This study demonstrates the possibility of using non-necrosis markers, in this case BNP, to augment clinical, ECG and troponins tools in risk stratification of patients across the spectrum of ACS.PubMedCrossRefGoogle Scholar
- 25.Bar-Or D, Winkler JV, Vanbenthuysen K, et al.: Reduced albumin- cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J. 2001, 141:985–991.PubMedCrossRefGoogle Scholar
- 26.Okamoto F, Sohmiya K, Ohkaru Y, et al.: Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med. 2000, 38:231–238.PubMedCrossRefGoogle Scholar